Alison Kodjak Alison Fitzgerald Kodjak is a health policy correspondent on NPR's Science Desk.
Alison Kodjak, photographed for NPR, 17 January 2019, in Washington DC.
Stories By

Alison Kodjak

Heather Bresch, CEO of Mylan Pharmacueticals, will face lawmakers' questions Wednesday about the company's steep price hikes for the company's life-saving EpiPen auto-injector. Dale Sparks/AP hide caption

toggle caption
Dale Sparks/AP

Mylan CEO Claims EpiPens Aren't As Profitable As Everyone Thinks

  • Download
  • <iframe src="https://www.npr.org/player/embed/494879607/494914776" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
John Labbe/Getty Images

Employees Are Paying A Bigger Chunk Of Health Insurance Costs

  • Download
  • <iframe src="https://www.npr.org/player/embed/493910307/493965938" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Michelle Kondrich for NPR

A Good Dentist Is Hard To Find In Rural America

  • Download
  • <iframe src="https://www.npr.org/player/embed/488416888/493584678" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Desperate Mother's Call Leads To Wis. Dental Clinics That Treat Rural Poor

  • Download
  • <iframe src="https://www.npr.org/player/embed/493021445/493573706" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

The FDA says there's no evidence that antibacterial soaps do a better job cleaning hands, and chemicals in them may pose health hazards. The FDA ban applies only to consumer products, not those used in hospitals and food service settings. Mike Kemp/Blend Images/Getty Images hide caption

toggle caption
Mike Kemp/Blend Images/Getty Images

County mosquito control inspector Yasser "Jazz" Compagines sprays a storm drain in Miami Beach to thwart mosquitoes that spread Zika. Alan Diaz/AP hide caption

toggle caption
Alan Diaz/AP

POLL: Most Americans Want Congress To Make Zika Funding A High Priority

  • Download
  • <iframe src="https://www.npr.org/player/embed/492103236/492203156" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Mylan, the maker of EpiPen, says it will sell a generic version for $300 for a two-pack, a price that consumer advocates say is still too high. The device is used to treat severe allergic reactions. Daniel Acker/Bloomberg via Getty Images hide caption

toggle caption
Daniel Acker/Bloomberg via Getty Images

Maker Of EpiPen To Sell Generic Version For Half The Price

  • Download
  • <iframe src="https://www.npr.org/player/embed/491797051/491848114" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Mother Calls EpiPen Price Hike 'A Matter Of Life And Death'

  • Download
  • <iframe src="https://www.npr.org/player/embed/491647599/491647600" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The cost of an EpiPen two-pack has risen more than 400 percent in recent years. The drug is used to halt severe allergic reactions. Joe Raedle/Getty Images hide caption

toggle caption
Joe Raedle/Getty Images

Discounts Aren't Enough to Halt Outrage At High EpiPen Prices

  • Download
  • <iframe src="https://www.npr.org/player/embed/491372193/491390054" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

An aggressive marketing campaign has made the EpiPen the go-to drug for treating anaphylaxis. Mark Zaleski/AP hide caption

toggle caption
Mark Zaleski/AP

EpiPen Manufacturer Says It Will Help With Out-Of-Pocket Costs

  • Download
  • <iframe src="https://www.npr.org/player/embed/491232665/491311810" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Aetna is the latest big health insurer to retreat from the exchanges established under the Affordable Care Act. Jessica Hill/AP hide caption

toggle caption
Jessica Hill/AP

Aetna Joins Other Major Insurers In Pulling Back From Obamacare

  • Download
  • <iframe src="https://www.npr.org/player/embed/490207169/490251859" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Express Scripts assures patients it has a policy of not putting cancer medicine or mental health drugs on the list of products it excludes from its formulary. Fuse/Getty Images hide caption

toggle caption
Fuse/Getty Images

Will Your Prescription Meds Be Covered Next Year? Better Check!

  • Download
  • <iframe src="https://www.npr.org/player/embed/489790412/490037655" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

In 2015, the Sandoz unit of drugmaker Novartis won Food and Drug Administration approval of a drug called Zarxio, which is similar to Amgen's Neupogen, a medicine that boosts the production of white blood cells. Sebastien Bozon/AFP/Getty Images hide caption

toggle caption
Sebastien Bozon/AFP/Getty Images